CASE SERIES

Diversities of Mechanism in Patients with VHL Syndrome and diabetes: A Report of Two Cases and Literature Review

Yanlei Wang*, Zhaoxiang Liu 🖻 *, Wenhui Zhao 🖻, Chenxiang Cao, Luqi Xiao 🖻, Jianzhong Xiao 🖻

Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, People's Republic of China

*These authors contributed equally to this work

Correspondence: Jianzhong Xiao, Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No. 168 Litang Road, Changping District, Beijing, 102218, People's Republic of China, Tel/Fax +8610-5611-9057, Email xjza01150@btch.edu.cn

Background: Von Hippel-Lindau (VHL) syndrome is characterized by tumorous lesions affecting multiple organs. Pancreatic involvement in VHL syndrome can present as endocrine tumors and pancreatic cysts, which can interfere with both exocrine and endocrine functions of the pancreas. Diabetes is an uncommon complication of VHL syndrome.

Purpose: This study aims to summarize the various mechanisms of diabetes in VHL syndrome by reporting two cases and conducting a literature review.

Methods: We analyzed the clinical and imaging data of two patients with VHL syndrome and diabetes. Additionally, we reviewed the existing literature to explore the clinical diversities and management strategies for VHL syndrome complicated with diabetes.

Results: The first patient presented with liver metastasis of pancreatic neuroendocrine tumor and multiple pheochromocytoma. After surgery, the patient's diabetic control improved, as evidenced by a significant reduction in insulin dosage. This indicates a potential insulin resistance due to elevated metanephrine levels prior to surgery and partial insulin deficiency caused by distal pancreatectomy. The second patient had multiple hemangioblastomas, as well as multiple pancreatic cysts and positive pancreatic islet autoantibodies. Diabetes in this case may be attributed to pancreatic lesions and the coexistence of autoimmune insulitis. A literature review of other patients with VHL combined with diabetes revealed multiple mechanisms, including increased catecholamine levels, pancreatic lesions, surgical removal of pancreatic tissue, endocrine treatment, and possibly the coexistence of autoimmune insulitis.

Conclusion: VHL syndrome complicated with diabetes involves diverse mechanisms.

Keywords: von Hippel-Lindau syndrome, diabetes, pancreatic neuroendocrine tumor

Introduction

Von Hippel-Lindau (VHL) syndrome is an autosomal dominant inherited disease with a prevalence of 1 in 36,000 live births and an average onset age of 26 years. It is caused by mutations in the *VHL* gene on the short arm of chromosome 3, leading to the inactivation of VHL protein. The normal VHL protein works to degrade hypoxia-inducible factors (HIFs). When VHL protein is inactivated, the inhibition of HIFs is weakened, causing hypoxic responses in the body. This affects glucose uptake, metabolism, angiogenesis, extracellular matrix generation, cell proliferation and directly promotes tumor formation.^{1,2} VHL syndrome is characterized by tumorous lesions affecting multiple organs, such as central nervous system and retinal hemangioblastomas (60–84%), pheochromocytoma (10–20%), renal cysts and renal cancer (25–60%), pancreatic neuroendocrine tumors (12–17%), etc.³ Depending on the severity of HIF accumulation, VHL syndrome can manifest as type 1 (low risk for pheochromocytoma), type 2A (high risk for pheochromocytoma and low risk for renal cell carcinoma), and type 2C (high risk for pheochromocytoma only).⁴

Diabetes, Metabolic Syndrome and Obesity downloaded from https://www.dovepress.com/ For personal use only. Pancreatic involvement in VHL syndrome can present as endocrine tumors and pancreatic cysts, along with other abnormalities in the pancreas. These lesions can interfere with both exocrine and endocrine functions of the pancreas. This article focuses on the features of VHL syndrome in combination with diabetes through the analysis of two case studies. We will examine existing data regarding VHL syndrome and its lesser-known correlation with significant glycemic abnormalities in the preoperative, perioperative, and postoperative stages. Additionally, we will discuss the clinical management of these cases.

Case I

On August 5, 2020, a 28-year-old female patient was admitted to our hospital with liver metastasis of pancreatic neuroendocrine tumor and combined with bladder and adrenal pheochromocytoma. In 2017, at the age of 25, the patient underwent transurethral resection of a bladder tumor after a routine physical examination revealing a mass in the bladder. At that time, her blood pressure and glucose levels were within normal range, and the pathology confirmed pheochromocytoma. During a follow-up examination in 2018, a solid cystic mass measuring approximately $4.8 \times 3.8 \times 5.6$ cm was found in the right adrenal gland, along with a fasting blood glucose level of 7.44mmol/L, which remained untreated. In March 2020, an MRI revealed multiple occupying lesions in the right adrenal gland, liver, and pancreas. Her fasting blood glucose level was 13.0 mmol/L, glycosylated hemoglobin (HbA1c) was 9.5%, fasting C-peptide was 0.68mg/mL, and 2-hour C-peptide was 4.65mg/mL. Additionally, levels of free methoxy norepinephrine (NMN) were 2020.0pg/mL (<145), and free methoxyepinephrine (MN) were 37.4pg/mL (<62). She was diagnosed with diabetes and received 11-9-8 units of Regular Insulin before meals and 24 units of NPH Insulin at night, with fasting blood glucose ranging from 9–10mmol/L and postprandial blood glucose ranging from 8-13mmol/L. She had also experienced a weight loss of 7 kg over the past three years.

The patient had a family history of VHL syndrome. Her father had undergone surgery for brainstem and spinal cord hemangioblastoma and had a pheochromocytoma in the left adrenal gland removed. Her brother had bilateral adrenal pheochromocytomas and had also undergone surgery. He was currently receiving monthly infusion of Sandostatin and daily oral treatment with Lenvatinib, and his blood glucose levels were normal.

On physical examination, the patient presented with a pulse rate of 101 beats/min, blood pressure of 113/70mmHg, height of 160m, weight of 45kg, and BMI of 17.6kg/m². The patient's skin was moist, and no abnormalities were detected during the cardiac and pulmonary exam. The abdomen was soft, and an approximately 8cm diameter hard mass was palpable in the upper abdomen with unclear boundaries, poor mobility, and no obvious tenderness. The blood test showed an elevated metanephrine level (Table 1). An enhanced CT scan revealed a possible right adrenal pheochromocytoma with multiple lesions in the pancreas and liver (Figure 1).

On August 12, 2020, the patient underwent surgery for complete resection of the right adrenal tumor, left liver S4 segment tumor, and distal pancreatectomy with resection of the pancreatic tail, while preserving approximately 4 cm of pancreatic tissue and the spleen. The postoperative pathology report revealed a pheochromocytoma in the adrenal gland and pancreatic neuroendocrine tumor (pNET) with liver metastasis. The patient and family members (father and brother) all tested positive for a heterozygous mutation of the *VHL* gene in intron 1 of the short arm of chromosome 3, specifically $c.340+3_340+10$ delinsCG (a deletion-insertion variant).

MN and NMN were found to be normal following the latest surgery. The patient was treated with Lenvatinib and Sandostatin and required a reduced insulin dosage from 52 IU in whole day to IDegAsp insulin 8 units before the main meal at noon, with fasting blood glucose of 5.1 mmol/L and postprandial blood glucose of 8.3 mmol/L. Glycosylated hemoglobin was monitored at 5.8–6.3%. Follow-up PET/CT one year after surgery showed no new tumors.

Case 2

On April 27, 2023, a 41-year-old male patient was admitted to our hospital with complaints of fatigue, decreased vision, and polydipsia. The patient's medical history dated back to 1999, when he underwent brain surgery because of dizziness, and the pathology confirmed cerebellar hemangioblastoma. In 2008, he was diagnosed with retinal hemangioblastoma and received laser therapy. In 2010, he was diagnosed with VHL syndrome after a mutation (c.642+70C>A in 3'-untranslated region of exon 3) was detected in the *VHL* gene. Subsequently, renal clear cell carcinoma was discovered

	Case (2020-7-18)	Case 2 (2023-4-28)	Normal Range		
ALT (U/L)	112.2	31.9	7~40		
AST (U/L)	78.6	32.2	13~35		
TBIL (μmol/L)	57.12	18.1	0–21		
DBIL (µmol/L)	45.51	7.3	<8		
BUN (mmol/L)	3.42	11.9	3.1~8.0		
Creatinine (µmol/L)	34.2	229	Female:41~73; Male:57~97		
Uric Acid (µmol/L)	283	514	Female: 155~357; Male:208~428		
NSE	9.53	Not measured	<16.3		
IAA (IU/mL)	NA	1.77	<0.9		
GAD (IU/mL)	NA	27.1	<10		
ICA (IU/mL)	NA	0.21	<0.9		
Fasting C-peptide (ng/mL)	0.68	1.62	1.1~4.4		
Fasting insulin (µU/mL)	Not measured	11.2	2.6~24.9		
2-hour C-peptide (ng/mL)	4.65	6.6			
2-hour insulin (μU/mL)	Not measured	72.6			
NMN (pg/mL)	2020.0	78.6	<145		
MN (pg/mL)	37.4	33.4	<62		
24h urine NMN (μg)	6930.0	12.6	<42.5		
24h urine MN (μg)	179.0	7.0	<57.1		

 Table I Laboratory Measurements of the Two Cases at Presentation

Abbreviations: NA, not acquired; ALT, glutamic-pyruvic transaminase. AST, glutamic-oxalacetic transaminase; TBIL, total bilirubin. DBIL, direct bilirubin; BUN, Blood urea nitrogen; IAA, insulin autoantibody; GAD, glutamic acid decarboxylase antibody; ICA, islet cell antibody; NMN, free methoxy norepinephrine; MN, free methoxyepinephrine.

and treated with percutaneous radiofrequency ablation (RFA) under full ultrasound monitoring. In 2014, the patient underwent surgical removal of cervical hemangioblastoma due to difficulty swallowing. Regular annual medical examinations were conducted, and recurrent tumors necessitated multiple surgeries. During a review in 2022, a spinal




Figure I Enhanced CT scan of the abdomen (patient one) revealed a mass in the right adrenal gland measuring 7.9cm×5.6cm×8.8cm, which showed obvious enhancement on the arterial phase and a non-enhancing necrotic center, consistent with a pheochromocytoma (**A**) (the red arrow). The scan also showed multiple metastases in the pancreas (the largest measuring approximately 6.0m×6.0cm×5.7cm, with irregular enhancement on the arterial phase) (**B**) (the red arrow), and possible multiple liver metastases (**A**) (the yellow arrow).

cord mass was discovered, and an enhanced magnetic resonance imaging (MRI) revealed the presence of multiple hemangioblastomas (Figure 2) in the spinal cord and cerebellar hemispheres, which were subsequently treated surgically.

One month before admission, the patient experienced fatigue and thirst, and his self-measured blood glucose level was 34 mmol/L, leading to a diagnosis of diabetes. He was initiated on insulin therapy, including 8–12 IU of aspartate insulin before meals and 18 IU of glargine insulin before bed. His fasting blood glucose ranged between 7 and 8 mmol/L, while his postprandial blood glucose 10–11 mmol/L. The patient did not experience any spontaneous tendency for ketosis or hypoglycemic episodes.

The patient denied any family history of diabetes or hemangioblastoma, and genetic testing of his parents and brother did not reveal any similar mutation in the *VHL* gene. On examination, the patient had a blood pressure of 132/94 mmHg, weighed 70 kg, had a height of 170 cm, BMI of 24 kg/m² and a waist circumference of 80 cm. No obvious abnormalities were detected during cardiac, pulmonary, or abdominal examination. However, an abdominal MRI revealed multiple cysts in the adrenal gland, liver, gallbladder, pancreas, and kidneys (Figure 3). Blood test showed positive pancreatic islet



Figure 2 Multiple hemangioblastomas (the red arrow) seen on thoracic spine MRI (patient two).




Figure 3 Abdominal MRI of patient two revealed multiple cysts in the pancreas (A) (the red arrow), as well as multiple cysts and solid nodules in both kidneys (B) (the red arrows).

autoantibodies (Table 1). The patient was prescribed 14 units of IDegAsp insulin before the main meal at noon, along with 5mg of Sitagliptin once daily. Subsequent blood glucose monitoring indicated fasting blood glucose of 6–7mmol/l and postprandial blood glucose of 8–10mmol/l.

Discussion

The Von Hippel-Lindau (VHL) syndrome encompasses various subtypes characterized by specific tumor types involved. Our first patient was classified as VHL type 2A although exhibiting clinical features similar to those associated with type 2B described in existing literature.⁵ The second case was designated as VHL type 1. The co-occurrence of VHL syndrome and diabetes is rare. Even in cases involving partial pancreatic surgery or complete pancreatic replacement due to multiple cysts, diabetes may not be present.⁶ However, diabetes can also be the primary manifestation of VHL syndrome.⁷ In VHL syndrome patients with pheochromocytoma, the prevalence of diabetes was found to be 16% (3/16),⁸ while in patients with VHL undergoing surgery for hemangioblastoma, the prevalence was 10.3% (6/58).⁹

In the case of our first patient, diabetes initially resulted from the secretion of norepinephrine by pheochromocytomas, leading to secondary diabetes. After surgery, the patient required much less insulin dosage, indicating a pronounced insulin-resistant state prior to the surgery. Literature reports suggest that catecholamines produced by pheochromocytomas can stimulate gluconeogenesis through β -receptor action, reduce insulin release through α -2 receptor interaction, and potentially induce insulin resistance by desensitizing β -adrenergic receptors.¹⁰ Blood glucose levels can be normalized after the removal of pheochromocytomas in VHL patients,¹¹ confirming their leading role in precipitating diabetes in certain cases of VHL.

In our first patient, diabetes persisted after pheochromocytoma surgery. Given the normal levels of catecholamines, it is likely attributed to pancreatic-related diabetes resulting from the partial removal of the pancreas. Similarly, our second patient developed pancreatic-related diabetes due to extensive cyst replacement of normal pancreatic tissue. VHL syndrome can cause various pancreatic lesions, including 47% pancreatic cysts, 11% serous cystadenomas, and 15% neuroendocrine tumors known as VHL-pNET.⁴ These VHL-pNET are typically nonfunctional and often present as multiple lesions.¹¹ While cases of diabetes associated with these pancreatic lesions are sporadically documented in the literature (Table 2), it is intriguing to note that these cases generally lack the manifestations of exocrine pancreatic dysfunction, such as steatorrhea, which differentiates them from conventional type 3C diabetes. Within VHL-related pancreatic lesions, endocrine dysfunction appears to be more prominent than exocrine dysfunction. Furthermore, our second patient also exhibited positive pancreatic islet autoantibodies, an observation previously unreported in the literature. This suggests the presence of potential autoimmune pancreatic insulitis in VHL patients.

A comprehensive search was conducted on PubMed. Two hundred articles were found by searching for "Von Hippel-Lindau syndrome" along with "diabetes", "glucose", or "insulin". Among them, 188 articles were irrelevant, 2 articles were not found, and 10 articles were included in the statistics. Additionally, 6 relevant articles were found from reviews, making a total of 16 articles included (Table 2). Based on the findings from these reports, the relationship between VHL syndrome and diabetes can be summarized as follows: (1) pheochromocytoma manifestation in VHL syndrome can lead to secondary diabetes; (2) pancreatic diabetes may occur when VHL syndrome presents as pancreatic neuroendocrine tumors or multiple cysts; (3) insulin-dependent diabetes mellitus may occur in combination with pancreatic islet autoantibodies; (4) non-insulin dependent diabetes mellitus may occur in individuals with a family history of diabetes after the use of somatostatin analogs, with an incidence rate of approximately 5% (5/101).²⁶ Despite severe pancreatic lesions were observed in the reported cases, some residual pancreatic function remained, indicating the compensatory ability of the remaining pancreatic tissue. Blood sugar levels can be effectively controlled using a simple regimen of insulin combined with oral medications.

Cases	Age	Sex	Pancreas Lesion	Diabetic Treatment	Type of Diabetes or etiology of diabetes	Renal	CNS	Pheo	Retina	VHL gene mutation
Huang, Y. et al, 2022 ¹²	34	F	Multiple cysts	NA	Type 2 diabetes mellitus	N	Y	N	Y	c.233A>G (p.Asn78Ser)
Belaid, R. et al, 2020 ¹¹	17	F	None	Normal glucose after adrenalectomy	Secondary to pheochromocytoma	Ν	N	Y	N	c.191G >C (p.Arg64Pro
Giri, S. et al, 2020 ¹³	34	F	Multiple cysts	NA	Pancreatic etiology	Ν	Y	N	N	NA
Saowapa, S. et al, 2019 ¹⁴	42	М	Multiple cysts	Insulin therapy	Pancreatic etiology	Y	N	N	N	c.263G>A (p.Trp88Stop
Kaluarachchi, V. T. S. et al, 2018 ¹⁵	34	F	None	Metformin after adrenalectomy	Secondary to pheochromocytoma	N	Y	Y	Y	no mutation detected
Ayloo, S. et al, 2016 ¹⁶	66	F	Multiple cysts	NA	Type 2 diabetes mellitus	Y	Y	N	Y	NA
Panayi, C. et al, 2016 ¹⁷	44	F	Neuroendocrine tumor, total pancreatectomy	Insulin therapy	Pancreatic etiology	Y	Y	N	N	NA
Heo, S. J. et al, 2016 ¹⁸	74	М	None	Insulin therapy	NA	Y	Y	N	N	c.208G > A (p.Glu70Ly
Medina, D.C. et al, 2014 ¹⁹	41	F	Serous cystadenoma	Metformin, long-acting insulin	Type 2 diabetes mellitus	Y	N	N	N	NA
Ku, Y. H. et al, 2013 ²⁰	30	F	Multiple cysts	Insulin therapy	Pancreatic etiology,	Y	Y	N	N	c.291C del (p. Tyr78ThrfsTer158)
Violaris, K. et al, 2007 ²¹	51	F	Multiple cysts	NA	Pancreatic etiology	Y	Y	N	N	NA
Chew, E. Y. et al, 2005 ²²	29	М	NA	NA	Pancreatic etiology	Y	N	N	Y	NA
Mukhopadhyay, B. et al, 2002 ²³	40	F	Serous cystadenoma	Oral medication	Pancreatic etiology	Y	Y	N	Y	no mutation detected

Mukhopadhyay, B. et al, 2002 ²⁴	54	М	Serous cystadenoma	Oral medication	Pancreatic etiology	Y	Y	N	Ν	no mutation detected
Varghese, B. et al, 1999 ⁷	47	F	Multiple cysts	Dietary intervention	Pancreatic etiology	Y	Ν	N	Y	NA
Cheng, T. Y. et al, 1997 ²⁴	52	F	Serous cystadenoma, total pancreatectomy	Insulin therapy	Pancreatic etiology	N	Ν	N	Y	NA
Cornish, D. et al, 1984 ²⁵	56	F	Neuroendocrine tumor, a cyst	Oral medication	Pancreatic etiology, secondary to pheochromocytoma	Y	Ν	Y	Y	NA
Case I	28	F	Neuroendocrine tumor	Insulin therapy	Pancreatic etiology, secondary to pheochromocytoma	N	Ν	Y	Ν	c.340+3_340 +10delinsCG (in intron 1)
Case 2	41	М	Multiple cysts	Insulin therapy	Pancreatic etiology	Y	Y	Ν	Y	c.642+70C>A (in 3'- untranslated region)

Abbreviations: F, female; M, male; N, normal; Y, yes; NA, not acquired; Renal, renal cysts or renal cancer; CNS, central nervous system hemangioblastomas; Pheo, pheochromocytoma; Retina, retinal hemangioblastomas.

Conclusions

In conclusion, we presented two cases of VHL syndrome with distinct disease subtypes, pancreatic lesions, and diabetic mechanisms. Despite these differences, both cases demonstrated abnormal glucose metabolism prior to the onset of exocrine pancreatic dysfunction. Additionally, after undergoing treatment, individuals with VHL syndrome can effectively manage their blood glucose using relatively straightforward methodologies for glycemic reduction. This phenomenon may be attributed to the improvement in insulin resistance following the removal of pheochromocytoma, as well as the preservation of residual pancreatic function. This observation holds significance for the future management of blood glucose control in individuals with VHL syndrome.

Data Sharing Statement

All the data are fully available without restriction. All data generated or analyzed during this study are included in this published article.

Ethics Approval and Informed Consent

All procedures performed in this study involving human participants were in accordance with the ethical standards of the ethics committee of Tsinghua Changgung Hospital, and with the 1964 Helsinki declaration and its later amendments. Written informed consent was obtained from the patient and her parents included in the study. Publication of case report does not need ethical review in our institution.

Consent for Publication

Written informed consent for publication was obtained from the two patients. A copy of the written consent is available by request.

Acknowledgments

We thank the patient for granting permission to publish this information.

Author Contributions

All authors were involved in the care of the patient, made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Jianzhong Xiao is the guarantor of this work and had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

This study was financially supported by the Tsinghua Precision Medicine Foundation (Grant No. 100010104). The funding organization had no role in design or conduct of the study, collection, management, analysis, or interpretation of the data, preparation, review, or approval of the manuscript, or decision to submit the manuscript for publication.

Disclosure

The authors declare that there are no conflicts of interest regarding the publication of this article.

References

- 1. Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H. VHL gene mutations and their effects on hypoxia inducible factor HIFalpha: identification of potential driver and passenger mutations. *Cancer Res.* 2011;71(16):5500–5511. doi:10.1158/0008-5472.CAN-11-0757
- Anthony BD, Amit T, Kristin H, et al. Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the international VHL surveillance guidelines consortium and VHL Alliance. *Cancer.* 2023;129(19):2927–29403. doi:10.1002/cncr.34896

- 3. Penitenti F, Landoni L, Scardoni M, et al. Clinical presentation, genotype-phenotype correlations, and outcome of pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome. *Endocrine*. 2021;74(1):180–187. doi:10.1007/s12020-021-02752-8
- 4. Ganeshan D, Menias CO, Pickhardt PJ, et al. Tumors in von Hippel-Lindau syndrome: from head to toe-comprehensive state-of-the-art review. *Radiographics*. 2018;38(3):849–866. doi:10.1148/rg.2018170156
- 5. Wang X, Zhang N, Ning X, et al. Higher prevalence of novel mutations in VHL gene in Chinese von Hippel-Lindau disease patients. *Urology*. 2014;83(3):675 e671–675. doi:10.1016/j.urology.2013.09.069
- 6. Maeda S, Motoi F, Oana S, et al. Pancreatic neuroendocrine tumor with complete replacement of the pancreas by serous cystic neoplasms in a patient with von Hippel-Lindau disease: a case report. *Surg Case Rep.* 2017;3(1):105. doi:10.1186/s40792-017-0381-4
- 7. Varghese B, Stephens WP. A new diabetic patient with an abdominal mass. Postgrad Med J. 1999;75(882):249–250. doi:10.1136/pgmj.75.882.249
- Butz JJ, Yan Q, McKenzie TJ, et al. Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1. Surgery. 2017;162(6):1259–1269. doi:10.1016/j. surg.2017.08.002
- 9. Hidaka T, Ikawa F, Michihata N, et al. Perioperative surgical risks in patients with hemangioblastomas: a retrospective nationwide review in Japan. *World Neurosurg.* 2023;170:e21–e27. doi:10.1016/j.wneu.2022.10.042
- 10. Ronen JA, Gavin M, Ruppert MD, Peiris AN. Glycemic Disturbances in Pheochromocytoma and Paraganglioma. *Cureus*. 2019;11(4):e4551. doi:10.7759/cureus.4551
- 11. Belaid R, Oueslati I, Chihaoui M, Yazidi M, Grira W, Chaker F. A case of von Hippel-Lindau disease with bilateral pheochromocytoma and ectopic hypersecretion of intact parathyroid hormone in an adolescent girl. *Case Rep Endocrinol.* 2020;2020;8824640. doi:10.1155/2020/8824640
- 12. Huang Y, Hu W, Huang X. Retinal hemangioblastoma in a patient with Von Hippel-Lindau disease: a case report and literature review. *Front Oncol.* 2022;12:963469. doi:10.3389/fonc.2022.963469
- 13. Giri S, Sundaram S, Darak H, Kumar S, Bhatia S. Von Hippel-Lindau disease presenting as obstructive jaundice. ACG Case Rep J. 2020;7(2): e00324. doi:10.14309/crj.00000000000324
- Saowapa S, Ativitavas T, Sriphrapradang C. Bilateral scrotal masses as a clue to diagnosis of genetic disease. Am J Med Sci. 2020;359(4):250–251. doi:10.1016/j.amjms.2019.11.014
- Kaluarachchi VTS, Bulugahapitiya U, Arambewela M, Gunathilake S. Successful management of pheochromocytoma detected in pregnancy by interval adrenalectomy in a VHL patient. Case Rep Endocrinol. 2018;2018:9014585. doi:10.1155/2018/9014585
- Ayloo S, Molinari M. Pancreatic manifestations in von Hippel-Lindau disease: a case report. Int J Surg Case Rep. 2016;21:70–72. doi:10.1016/j. ijscr.2016.02.031
- Panayi C, Antoun N, Sandford R. Bulbar dysfunction and aspiration pneumonia due to a brainstem haemangioblastoma: an unusual complication of von Hippel-Lindau disease. *BMJ Case Rep.* 2016;2016. doi:10.1136/bcr-2016-217076
- 18. Heo SJ, Lee CK, Hahn KY, et al. A case of von Hippel-Lindau disease with colorectal adenocarcinoma, renal cell carcinoma and hemangioblastomas. *Cancer Res Treat*. 2016;48(1):409–414. doi:10.4143/crt.2014.299
- 19. Medina DC, Osorno R, Boutros CN. Biliary and gastric drainage in advanced pancreatic serous cystadenoma and portal hypertension in Von Hippel-Lindau syndrome. J Gastrointest Oncol. 2014;5(2):E50-3. doi:10.3978/j.issn.2078-6891.2014.017
- 20. Ku YH, Ahn CH, Jung CH, et al. A novel mutation in the von Hippel-Lindau tumor suppressor gene identified in a patient presenting with gestational diabetes mellitus. *Endocrinol Metab.* 2013;28(4):320–325. doi:10.3803/EnM.2013.28.4.320
- 21. Violaris K, Siozos T, Skoulios N, Sakellariou P. A case report of a family with 7 patients of the Von Hippel-Lindau disease. *Surg Neurol.* 2007;68 (6):650–654. doi:10.1016/j.surneu.2006.11.040
- 22. Chew EY. Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. Trans Am Ophthalmol Soc. 2005;103:495-511.
- Mukhopadhyay B, Sahdev A, Monson JP, Besser GM, Reznek RH, Chew SL. Pancreatic lesions in von Hippel-Lindau disease. *Clin Endocrinol.* 2002;57(5):603–608. doi:10.1046/j.1365-2265.2002.01637.x
- 24. Cheng TY, Su CH, Shyr YM, Lui WY. Management of pancreatic lesions in von Hippel-Lindau disease. World J Surg. 1997;21(3):307-312. doi:10.1007/s002689900234
- Cornish D, Pont A, Minor D, Coombs JL, Bennington J. Metastatic islet cell tumor in von Hippel-Lindau disease. Am J Med. 1984;77(1):147–150. doi:10.1016/0002-9343(84)90450-9
- 26. Halperin R, Tirosh A. Non-interventional management of advanced pancreatic neuroendocrine neoplasms in patients with von Hippel-Lindau disease. *Cancers*. 2023;15(6):1739. doi:10.3390/cancers15061739

Diabetes, Metabolic Syndrome and Obesity

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal

If in DovePress

1619